China Meheco subsidiary gets drug approval for cholesterol treatment

China Meheco Co. announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for Rosuvastatin Calcium and Ezetimibe Tablets (I). This medication, containing 10mg of rosuvastatin calcium and 10mg of ezetimibe per tablet, is intended for treating hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH), with the combination expected to enhance lipid-lowering efficacy and reduce cardiovascular events. The total investment in this drug to date is approximately RMB 2,439万元.

The drug was first launched in the European Union in July 2014, followed by Japan and the United States, and in China in December 2023. As of the announcement date, three other manufacturers in China have also received approval for this drug. According to third-party data, the drug's sales in China’s major markets were approximately RMB 146万元 (for the original research drug only) in 2024, with projections of RMB 2,353万元 for the first three quarters of 2025.

This approval is expected to enrich China Meheco's product line and provide valuable experience for future generic drug development. However, the company cautions investors about potential sales not meeting expectations due to uncertainties in national policies and market conditions.